Use of biochemical markers to study and follow patients with osteoarthritis.
Osteoarthritis is characterized by progressive destruction of articular cartilage and subchondral bone and synovial reaction. Radiologic findings that form the basis of the diagnosis of osteoarthritis are poorly sensitive to detect early disease and for monitoring progression of joint damage. Blood-based proteomic analyses suggest that biochemical alterations can be observed well before radiologic damage is evidenced. New cartilage-specific markers, including assays for type II collagen synthesis and degradation, have been developed. Recent prospective studies indicate that blood and urine levels of these new markers are associated with progression of joint damage. Biological markers respond rapidly to treatment and therefore will certainly play an important role in the development and the monitoring of disease-modifying therapies. Because osteoarthritis involves different tissues and complex biologic processes, a combination of different biochemical markers appears to be the most promising diagnostic strategy.
Garnero
Patrick
P
Synarc, Molecular Markers, Le Buroparc Batîment T4, 16 rue Montbrillant, 69003 Lyon, France. patrick.garnero@synarc.com
D015415:Biomarkers; D001842:Bone and Bones / Q000378:metabolism* / Q000473:pathology; D002358:Cartilage, Articular / Q000378:metabolism / Q000473:pathology; D018450:Disease Progression; D006801:Humans; D010003:Osteoarthritis / Q000175:diagnosis* / Q000378:metabolism* / Q000503:physiopathology; D013583:Synovial Membrane / Q000378:metabolism / Q000473:pathology
D015415:Biomarkers